Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations

Disha Khanna[1]*, Treshita Dey[2], Ellen Blanchard-Cavagis[3], Beverley Gonsalves[4], Aaron Benedict[5], Mebin Job[6], Denise Omoregie[6], Sreejana Basu[7], Olivia Benny[6], Akash Maniam[8], Aruni Ghose[9]

[1]The University of Buckingham Medical School, Crewe, United Kingdom; [2]Sanjay Gandhi Institute of Medical Sciences, Lucknow, India; [3]Université Paris Cité, France; [4]Kings College London, United Kingdom; [5]Barts and The London School of Medicine and Dentistry, London, United Kingdom; [6]School of Medicine, Keele University, United Kingdom; [7]University College London, United Kingdom; [8]Department of Medical Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom; [9]Velindre Cancer Service, Velindre University NHS Trust, Cardiff, United Kingdom; *Corresponding: d.khanna@buckingham.ac.uk

INTRODUCTION & BACKGROUND

First-line immune checkpoint inhibitor (ICI)-based combinations have transformed metastatic clear cell renal cell carcinoma (mRCC) outcomes, establishing a new therapeutic standard on a global scale. [5]

However, the clinical influence of patient ethnicity on the efficacy and safety of these regimens remains poorly characterized. This critical knowledge gap is primarily driven by a historical underreporting of detailed demographic and racial variables in major landmark clinical trials. [5]

Consequently, benchmarking clinical performance across diverse ethnic cohorts is absolutely essential to verify therapeutic consistency and ensure clinical equity for all patients globally. [5]

AIM OF THE STUDY

To conduct a rigorous, ethnicity-based systematic benchmarking analysis of European Society for Medical Oncology (ESMO) guideline-recommended first-line ICI-based combination regimens in patients with clear-cell metastatic renal cell carcinoma (mRCC), comparing quantitative and qualitative outcomes to identify data disparities. [5, 6]

METHODOLOGY & LITERATURE SEARCH

• **Database Queries:** We performed a comprehensive, systematic literature search across PubMed, Embase, and the Cochrane Library databases. [6]

• **Inclusion Criteria:** Adult patients diagnosed with clear-cell mRCC who were treated with any of the four standard-of-care, guideline-recommended regimens: Ipilimumab+Nivolumab, Nivolumab+Cabozantinib, Pembrolizumab+Axitinib, or Pembrolizumab+Lenvatinib. [6]

• **Statistical Meta-Analysis:** A random-effects model calculated pooled Objective Response Rates (ORR) and 95% Confidence Intervals (CI) specifically for the Ipilimumab/Nivolumab cohort, stratified by Asian versus Caucasian ethnicity. [6, 7]

• **Survival Mapping:** Progression-Free Survival (PFS) was analyzed descriptively due to extreme reporting heterogeneity in clinical literature. [6]

ESMO GUIDELINE-RECOMMENDED REGIMENS & DEMOGRAPHIC GAPS

Regimen	Class	Mechanism / Target	ESMO Status	Ethnic Data & Reporting
Ipi + Nivo	Dual ICI	CTLA-4 + PD-1 inhibitors	1st Line Standard (Level 1A)	**High:** Robust demographic details in clinical registries, enabling our meta-analysis pool of 3,489 patients. [7]
Nivo + Cabo	TKI-ICI	PD-1 + VEGFR/MET inhibitors	1st Line Standard (Level 1A)	**Low:** Extremely sparse data. Separate reporting for Asian versus Caucasian subgroups is severely lacking. [8]
Pem + Axi	TKI-ICI	PD-1 + VEGFR inhibitors	1st Line Standard (Level 1B)	**Low:** Sparse. Trial cohorts fail to publish granular race-stratified survival or safety outcomes. [8]
Pem + Len	TKI-ICI	PD-1 + Multi-Targeted TKIs	1st Line Standard (Level 1B)	**Severe:** Profoundly deficient reporting for non-white, Black, or Mixed-ethnicity cohorts across landmark trials. [8]

QUANTITATIVE RESULTS & SUBGROUP ANALYSIS

Our systematic search and meta-analysis of the first-line dual ICI combination (Ipilimumab plus Nivolumab) encompassed a highly robust, multi-center pool of 3,489 total patients (comprising 1,760 Asian patients and 1,729 Caucasian patients). [7]

• **Objective Response Rate (ORR):** Quantitative random-effects pooling demonstrated a pooled ORR of 44% (95% CI: 39%–49%) within the Asian clinical cohorts, compared to a pooled ORR of 40% (95% CI: 35%–46%) in the Caucasian cohorts. [7]

• **Statistical Equivalence:** Formal statistical testing confirmed that the minor numerical variance in response rates between Asian and Caucasian patients was not statistically significant (p = 0.2980, p > 0.05), indicating consistent dual immune blockade response parameters. [7, 9]



Figure 1: Random-effects meta-analysis forest plot of Objective Response Rate (ORR) for Asian vs. Caucasian cohorts on Ipilimumab plus Nivolumab, demonstrating clinical and biological equivalence. [1, 7]

DESCRIPTIVE SYNTHESIS: PFS MAP & CRITICAL GAPS

• **Progression-Free Survival (PFS):** Descriptive mapping of median PFS (months) demonstrated massive graphical and clinical overlap between Asian and Caucasian patients across all studied regimens, revealing no substantial ethnicity-driven disparities in disease control. [8]

• **Severe Clinical Gaps:** Efficacy data for Black and Mixed-ethnicity populations was 'profoundly deficient' across all published clinical trial reports and real-world database papers. [8] This total absence of standardized data made it statistically impossible to perform any subgroup pooling or meta-analysis for these underserved cohorts, which represents a critical disparity in medical literature. [8]



Figure 2: Descriptive mapping of median PFS (months) across standard mRCC regimens by ethnicity, showing massive overlap and highlighting severe data-sparsity for non-white cohorts. [4, 8]

CLINICAL DISCUSSION & HETEROGENEITY

• **Therapeutic Equivalence of Dual ICI:** Our findings provide high clinical confidence that the gold standard first-line regimen of Ipilimumab plus Nivolumab possesses high therapeutic equivalence between Asian and Caucasian patients. Minor numerical differences in ORR are non-significant, confirming biological and clinical consistency. [7, 9]

• **The Heterogeneity Challenge:** The extremely high statistical heterogeneity in both arms (I^2 = 73.8% in Asians, I^2 = 85.1% in Caucasians) strongly suggests that clinical factors—such as age, performance status, tumor burden, metastatic site, and healthcare delivery systems—play a far more substantial role in driving outcomes than coarse racial/ethnic definitions. [7, 9]

• **The Non-White Underrepresentation Crisis:** While Asian vs. Caucasian outcomes are relatively comparable, the reporting of outcomes for Black and Mixed-ethnicity patients remains severely lacking. Trial cohorts rarely stratify survival beyond binary race categories, which limits the optimization of precision immunotherapy for a global population. [8, 9]

• **TKI-ICI Underreporting:** Novel TKI-ICI combinations (such as Pembrolizumab+Lenvatinib and Nivolumab+Cabozantinib) lack granular, race-stratified reporting in both registrational and real-world cohorts, hindering robust benchmarking comparisons. [8]

CONCLUSIONS

1. First-line Ipilimumab plus Nivolumab shows equivalent, robust, and consistent clinical efficacy (ORR, PFS) across both Asian and Caucasian mRCC patients, giving clinicians confidence in its global therapeutic utility. [9]

2. The minor absolute variance in pooled ORR (44% in Asian vs. 40% in Caucasian cohorts) was statistically nonsignificant (p = 0.2980), supporting the absence of ethnic disparities in response. [7, 9]

3. High statistical heterogeneity indicates that treatment selection should be guided by individual clinical risk profiles rather than coarse geographical or ethnic assumptions. [7, 9]

FUTURE DIRECTIONS

• **Standardized Demographic Mandates:** Global oncological registries and future clinical trial designs must enforce standardized, granular reporting of race and ethnicity data as a mandatory requirement for publication. [9]

• **Real-World Evidence Networks:** Cultivate large-scale, international multicenter real-world databases to actively monitor and compare outcomes of novel TKI-ICI regimens in racially diverse and historically underrepresented cohorts. [8]

• **Focus on Precise Biomarkers:** Transition therapeutic optimization from coarse demographic labels to precise molecular biomarkers, including the immune microenvironment, pharmacogenomics, and genomic signatures. [9]